Wolters Kluwer Health - Lippincott Williams & Wilkins

Registered Users

User Name:
Password:
Register   Forgotten Password
Enter your email address:
  • Conferences
  • Free Content
  • Hot Topics
  • News
  • Archive
  • Contact Us
  • Home
  • Publish With Us
  • Partnerships in Focus
  • Current Focus
  • Conference Focus
  • Society Partners
  • News
  • Contact Us
  • Resources
  • Download Centre
  • About Us
  • Sustainability
  • Register

Cancer Prevention banner

You are here: Home » Gastroenterology » GGT and AFP predict SVR in CHC

Gamma-glutamyl transpeptidase and a-fetoprotein: are they predictors of treatment response in patients with chronic hepatitis C?

Cover of European Journal of Gastroenterology & HepatologyEl Samiee et al
Egyptian Liver Journal 1 (1) April 2011
ISSN: 2090-6226 • Frequency: 3/year • Subscribe Now • Journal Website

Hepatitis C virus is a leading cause of chronic liver disease. Elevated serum a-fetoprotein (AFP) has been used as a marker for hepatic regeneration after the destruction of hepatocyte in viral hepatitis. Recently, c-glutamyl transpeptidase (GGT) has also been taken into account in the evaluation of patients with chronic hepatitis C (CHC). This study aimed to examine the association between serum AFP and serum GGT levels, and treatment outcome in patients with CHC treated with pegylated interferon and ribavirin.

Read this article
 
Don't miss out - further Free LWW Content is available for registered users! Log into your account or register here to read these articles
 
 
 
 
Bookmark and Share

Oncology button
Radiology button
Pathology Archive
Mental Health button
HIV AIDS Focus
Emergency Medicine button
Gastroenterology button
Neurology button
Cardiology button
Infectious Diseases Archive
Aneasthesiology Archive
Conferences


©2012 Lippincott Williams & Wilkins
Judd Associates: Sussex Web Design
  • Site Map
  • Accessibility
  • Privacy
Follow us on Facebook and Twitter